Cor Vasa 2005, 46(6):251-254
The HOPE for Europe is PEACE: ACE inhibitors in CHD secondary prevention
- 1 Interní-kardiologická klinika, Fakultní nemocnice Brno
- 2 I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno, Česká republika
PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition Trial) is a multicentric randomized, double-blind study, comparing treatment with the ACE inhibitor trandolapril and placebo in patients with confirmed coronary heart disease without heart failure, with an ejection fraction over 0.4 and a BPd < 100 mm Hg. A total of 8,290 patients were enrolled and followed for 4.8 years. The primary endpoint (death, nonfatal MI, CABG and PCI) was not affected (21.9% vs. 22.5%, p = 0.43). There was a decrease in hospitalization or death rates due to heart failure (2.8% vs. 3.7%, p = 0.02) and a decrease in new-onset diabetes mellitus (9.8% vs. 11.5%, p < 0.01). 72% of the patients had had revascularization and 70% were taking lipid-lowering drugs.
Keywords: ACE inhibitors; Secondary prevention; Trandolapril; Diabetes mellitus
Published: June 1, 2005 Show citation